Epimer-specific actions of hepoxilins A3 and B3 on PAF- and bradykinin-evoked vascular permeability in the rat skin in vivo.
Wang
M M
MM
Research Institute, Hospital for Sick Children, Toronto, Canada.
Demin
P M
PM
Pace-Asciak
C R
CR
D015126:8,11,14-Eicosatrienoic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D001798:Blood Proteins / Q000378:metabolism; D001920:Bradykinin / Q000494:pharmacology*; D002199:Capillary Permeability / Q000187:drug effects*; D004357:Drug Synergism; D007271:Injections, Intradermal; D008297:Male; D010972:Platelet Activating Factor / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D012039:Regional Blood Flow / Q000187:drug effects; D012867:Skin / Q000098:blood supply* / Q000187:drug effects
D001798:Blood Proteins; D010972:Platelet Activating Factor; C022948:10-hydroxy-11,12-epoxyeicosa-5,8,14-trienoic acid; C038243:8-hydroxy-11,12-epoxyeicosa-5,9,14-trienoic acid; D015126:8,11,14-Eicosatrienoic Acid; D001920:Bradykinin